Ivax Generic Paclitaxel Clears FDA; Bristol Patent Case Pending In N.Y.
FDA has approved Ivax' generic version of the anticancer agent paclitaxel despite Bristol-Myers Squibb's announced relisting of a recently issued patent in the "Orange Book."
FDA has approved Ivax' generic version of the anticancer agent paclitaxel despite Bristol-Myers Squibb's announced relisting of a recently issued patent in the "Orange Book."